Detection of Early Idiopathic Pulmonary Fibrosis

The Role of the miR200 Family in the Restoration of Normal Lung Homeostasis and Detection of Early IPF

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT03457935

Enrollment

450

Registered

2018-03-08

Start date

2018-04-10

Completion date

2026-08-30

Last updated

2025-12-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Idiopathic Pulmonary Fibrosis

Brief summary

The purpose of the study is to determine if miR200 family may serve as a biomarker of IPF.

Interventions

OTHERblood samples

Blood samples

Study design

Observational model

COHORT

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Yes

Inclusion criteria

for IPF Patients: * Informed consent * Subjects ≥ 40 y.o. * Naive patients with no IPF treatment * IPF diagnosis based on the ATS/ERS/JRS/ALAT criteria Inclusion Criteria for non-IPF ILD Patients: * Informed consent * Subjects ≥ 18 y.o. * ILD diagnosis

Exclusion criteria

* HIV * Hepatitis B * Hepatitis C * Pregnant or lactating women inclusion criteria for controls: informed consent \>18 years old; no lung diseases

Design outcomes

Primary

Measure	Time frame	Description
To determine miR200 levels (fold change) in blood samples.	Baseline (one time).	MicroRNAs (miRs) are noncoding small RNAs, which regulate numerous physiological and pathological processes. miR200 levels will be measured in blood samples collected from control subjects, non-IPF ILD and IPF patients. These samples will be used for identifying biomarkers for IPF.

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026